Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 2Phase NA 1Phase 2/3 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 234Breast Neoplasms 234Prostatic Neoplasms 172Multiple Myeloma 154Neoplasms 135Colorectal Neoplasms 126Leukemia, Myeloid, Acute 123Lung Neoplasms 109Neoplasm Metastasis 101Squamous Cell Carcinoma of Head and Neck 94Carcinoma, Hepatocellular 91Melanoma 89Lymphoma 85Triple Negative Breast Neoplasms 77Pancreatic Neoplasms 76Ovarian Neoplasms 72Sarcoma 71Brain Neoplasms 66Lymphoma, Large B-Cell, Diffuse 65Carcinoma, Renal Cell 65Recurrence 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Head and Neck Neoplasms 56Lymphoma, Non-Hodgkin 55Leukemia, Lymphocytic, Chronic, B-Cell 55Stomach Neoplasms 52Hematologic Neoplasms 52Endometrial Neoplasms 52Urinary Bladder Neoplasms 51Rectal Neoplasms 50

Interventions

pertuzumab 2atezolizumab 1Trastuzumab 1Paclitaxel 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × HER2-positive Breast Cancer × 90 days × Clear all
NCT03125928 2026-05-22

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Fox Chase Cancer Center

Phase 2 Active not recruiting
16 enrolled
Breast

HER2-positive Breast Cancer

NCT06445400 2026-05-13

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Active not recruiting
83 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡